医学信息2024，Vol.37Issue(16)：52-54,63,4.DOI:10.3969/j.issn.1006-1959.2024.16.010
罗沙司他与促红素在血液透析患者肾性贫血中的效果比较
Comparison of the Effects of Rosalrestat Erythropoietin on Renal Anemia in Hemodialysis Patients
摘要
Abstract
Objective To compare the clinical efficacy of rosalrestat and erythropoietin in the treatment of renal anemia in hemodialysis patients.Methods The clinical data of 78 hemodialysis patients with renal anemia admitted to Longnan First People's Hospital from January to December 2022 were selected and divided into control group and observation group according to different treatment methods,with 39 patients in each group.The control group was treated with erythropoietin,and the observation group was treated with rosalrestat.The iron metabolism indexes[hepcidin(Hepc),transferrin(TRF),transferrin saturation(TSAT),serum ferritin(SF)],anemia indexes[hematocrit(Hct),hemoglobin(Hb)and red blood cell count(RBC)]and adverse reactions(heart failure,headache,nausea,diarrhea)were compared between the two groups.Results After treatment,the level of Hepc in the observation group was lower than that in the control group,and the levels of TRF,TSAT and SF were higher than those in the control group,the differences were statistically significant(P＜0.05).After treatment,the levels of Het,Hb and RBC in the observation group were higher than those in the control group,and the differences were statistically significant(P＜0.05).The incidence of adverse reactions in the observation group(5.13％)was lower than that in the control group(28.21％),and the difference was statistically significant(P＜0.05).Conclusion Compared with erythropoietin,rosalrestat is more effective in the treatment of renal anemia in hemodialysis patients,which is beneficial to improve iron metabolism and anemia,and has high safety.关键词
罗沙司他/促红素/血液透析/肾性贫血/铁代谢Key words
Rosalrestat/Erythropoietin/Hemodialysis/Renalanemia/Iron metabolism分类
医药卫生引用本文复制引用
叶益舟,凌铭培,余娟,李小生..罗沙司他与促红素在血液透析患者肾性贫血中的效果比较[J].医学信息,2024,37(16):52-54,63,4.基金项目
赣州市科技计划项目(编号:GZ2023ZSF470) （编号:GZ2023ZSF470）
